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Background: Cardiovascular diseases (CVD) are a leading cause of death worldwide including the Middle East. This is
caused in part by the dysregulation of adipose tissue leading to increased production of pro-inflammatory adipokines
and reduction in cardio-protective adipokines such as adiponectin. Ethnicity has been recognized as a major factor in
the association between CVD risk factors and the different circulating adipokines. In this study, for the first time, the
relationship between traditional cardiovascular risk factors, Metabolic Syndrome (MetS) and circulating level of
adipokines in Arab ethnicity was investigated.
Methods: We conducted a population-based cross-sectional survey on 379 adult Arab participants living in Kuwait.
Traditional cardiovascular risk factors such as blood pressure (BP), low density lipoprotein (LDL) and triglyceride (TG)
were measured. Plasma levels of circulating Leptin, Plasminogen Activator Inhibitor (PAI-1) visfatin, adiponectin, resistin
and adipsin were assessed using the multiplexing immunobead-based assay.
Results: Circulating levels of High sensitivity C-Reactive Protein (hsCRP), Leptin, PAI-1 and adiponectin were significantly
higher in Arab women than men (p < 0.0001). In multi-variate analysis, the homeostasis model assessment-insulin
resistance (HOMA-IR) and body mass index (BMI) showed strong association with most of the biomarkers (p < 0.05).
HsCRP showed significant association with all risk factors (p < 0.05). Leptin, PAI-1 and adipsin showed significant
positive correlation with BMI, unlike adiponectin which showed inverse correlation (p < 0.05). Subjects in the highest
tertile of leptin, PAI-1 and hsCRP had higher odds of having Metabolic Syndrome (MetS) (odd ratio [OR] = 3.02, 95%
confidence interval [CI] = 1.47 – 6.19) and (OR = 2.52, 95% CI = 1.45 – 4.35), (OR = 4.26, 95% CI = 2.39 – 7.59)
respectively. On the other hand subjects with highest tertile of adiponectin had lower odds of having MetS
(OR = 0.22, 95% CI = 0.12 – 0.40). Leptin, PAI-1 and hsCRP showed significant positive association with increased
MetS components (P-trend <0.05), while adiponectin was negatively associated with increased MetS components
(P-trend <0.0001).
Conclusion: Our results show positive association between hsCRP, leptin, PAI-1 with increased MetS components
and increase the odds of having MetS. Adiponectin on the other hand showed inverse correlation with MetS
components and associated with reduction in MetS. Overall, our data highlights the significant clinical value these
markers have in MetS especially hsCRP which can be used as good marker of low grade inflammation in Arabs.
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CVD are one of the leading causes of mortality world-
wide [1]. Due to the increase in obesity and MetS, CVD
mortality and morbidity are expected to increase even
higher posing a huge risk to public health and health
care systems around the globe [1]. CVD include cardio-
myopathy, cardiac dysrhythmias, myocarditis, myocar-
dial infarction, hypertension and atherosclerosis [2]. A
number of risk factors have been identified to be associ-
ated with CVD such as hypertension, obesity, smoking,
life style, hyperlipidaemia, Type 2 Diabetes (T2D) and
MetS [2]. MetS is a cluster of metabolic risk factors that
has been shown to cause a two fold increase in cardio-
vascular outcomes and a 1.5 fold increase in all-cause
mortality [3-5]. Central obesity, dyslipidemia, elevated
blood pressure; elevated fasting glucose and insulin re-
sistance are the most pivotal components of MetS [6].
MetS is also characterized by a chronic low grade in-
flammation state which can explain the increased CVD
and T2D risk [7]. MetS is also characterized by a low
grade inflammation with increased hsCRP level. HsCRP
is a marker of low grade inflammation which was shown
in many studies to be higher in subjects with MetS and
it associates with increased risk of CVD and T2D [7].
The association between MetS, obesity, T2D and CVD
is intertwined due to their role in the disruption of
homeostasis of important factors such as inflammatory
markers and stress related markers in addition to other
adipokines produced by adipose tissue [2]. Adipose tis-
sue is an organ that was originally thought to be simply
a storage organ for triacylglycerol [8]. Recently, it has
been recognized as a metabolically active endocrine
organ that affects various biological processes such as
energy homeostasis, feeding, immunity and glucose and
lipid metabolism amongst others [9]. The main cell types
residing in adipose tissues are adipocytes, preadipocytes,
fibroblasts, endothelial cells, and immune cells such as
macrophages and lymphocytes [9]. Disruption of normal
adipose tissue function; as shown with increased obesity;
leads to the production and release of proinflammatory,
atherogenic, and diabetogenic agents [9]. Consequently,
various adipokines such as TNF-α, IL-6, leptin, adipo-
nectin, visfatin, PAI-1 and others are secreted to the
blood stream [8,10]. The association between the differ-
ent adipokines and CVD risk factors has been under in-
vestigation to understand their role in cardio-metabolic
risk [9]. Adiponectin and PAI-1 for example, are two
adipokines with opposing effects on CVD, where adipo-
nectin is thought to be cardio-protective [11] and PAI-1
is atherogenic [12].
Ethnicity has been suggested as a major factor in de-
termining expression level of various metabolic markers
and their association with CVD, T2D and MetS [13-17].
Association between adipokines and CVD risk factorsand MetS are not very well studied in the Arab popula-
tion [18]. This prompted our effort to understand the re-
lationship between CVD risk factors and MetS with
hsCRP and a group of adipokins in this population. We
present population based cross-sectional study in an
Arab population living in Kuwait that look at the associ-
ation between MetS and CVD risk factors such as high
fasting blood glucose, high LDL, BMI with a number of
adipokines such as leptin, PAI-1 and adiponectin in
addition to hsCRP. We also aim to identify markers that
can independently associate with MetS and could poten-




This is a cross-sectional population-based survey under-
taken on 379 adult Arab expatriates living in the state of
Kuwait. According to the 2011 census, 67.7% of the
Kuwait population is expatriates hailing mostly from
Arab countries, Indian subcontinent and South East
Asia. Subjects originating from Arab countries such as
Egypt, Syria, Lebanon, Palestine, Jordan and/or Arab gulf
countries were classified as Arabs. Subjects were selected
randomly from the computerized register of the Public
Authority of Civil Information. Participants with history
of CVD were excluded from the study. The study con-
formed to the principles outlined in the Declaration of
Helsinki and was approved by the institutional Ethical
Review Committee at Dasman Diabetes Institute. An in-
formed written consent was obtained from all the partic-
ipants before their enrolment in the study. This study
was carried out between June 2011 and August 2012.
Anthropometric and physical measurements
Physical and anthropometric measurements included
body weight, height, waist circumference (WC) as well
as systolic blood pressure (SBP) and diastolic blood pres-
sure (DBP). Height and weight were measured, with par-
ticipants wearing light indoor clothing and bear-footed
using calibrated portable electronic weighing scales and
portable inflexible height measuring bars. Waist circum-
ference was measured using constant tension tape at the
end of a normal expiration, with arms relaxed at the sides,
the highest point of the iliac crest and the mid-axillary
line. BP was measured with Omron HEM-907XL Digital
sphygmomanometer. An average of 3 BP readings, with 5
to 10 minutes rest between each, was obtained. BMI was
calculated using the standard BMI formula: body weight
(in kilograms) divided by height (in meters squared).
Laboratory measurements
Blood samples were obtained after an overnight fasting
for at least 10 hours and analyzed for fasting glucose,
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lipid profiles that included TG, total cholesterol (TC),
LDL, and high-density lipoprotein (HDL). Glucose and
lipid profiles were measured on the Siemens Dimension
RXL chemistry analyzer (Diamond Diagnostics, Holliston,
MA). HbA1c was determined using the Variant™ device
(BioRad, Hercules, CA). All laboratory tests were per-
formed by certified nurses and technicians at the clinical
laboratories of DDI, using the Ministry of Health approved
methods and quality standards. Insulin resistance was cal-
culated using HOMA-IR formula: fasting blood glucose
(FBG) (mmol/L) x fasting Insulin (mU/L) / 22.5.
To measure adipokines, blood was drawn into EDTA
tubes. Plasma was obtained after centrifugation, aliquoted
and then stored at −80°C. Plasma levels of adipokines were
assessed using the multiplexing immunobead array plat-
form (Luminex, Austin, TX). We used the Human Dia-
betes 10-Plex kit consisting of leptin, PAI-1, resistin, and
visfatin) and 2-Plex kit consisting of adiponectin and adip-
sin (BioRad, Hercules, CA).). Experimental data was proc-
essed with Bio-Plex manager software version 6 (Bio-Rad,
Hercules, CA) using five-parametric curve fitting. HsCRP
secreted level was measured using ELISA kit (Biovendor,
USA). All the above mentioned assays were carried out ac-
cording the manufacturers procedures.
The current recommendations and updated guide-
lines for the definition, diagnosis and classification of
MetS, published by the International Diabetes Feder-
ation (IDF), were used [19]. MetS was defined by ab-
dominal obesity and at least two of: fasting blood
glucose values ≥ 5.6 mmol/L, hypertension was defined as
BP ≥ 130/85 mmHg, under treatment, or a self-report
of previously diagnosed hypertension. Hypertriglyc-
eridemia as ≥ 1.7 mmol/L and low HDL cholesterol
as < 1.03 mmol/L in men and < 1.29 mmol/L in women.
BMI between 18.5 and 24.9 was considered normal, 25 to
29.9, overweight, and equal to or higher than 30, was con-
sidered obese. Cutoffs for central obesity were adopted
from IDF; they were defined based on race and gender.
In our population WC ≥ 94 cm in men and ≥ 80 cm in
women was used.
Statistical analysis
Comparisons between clinical and biochemical profiles
between gender were made by Student’s t-test or Wilcoxon
test for non-parametric analyses in variables with non-
normal distribution. To assess difference in categorical
variables between male and female, Chi-Squared test was
used. Spearman’s correlation coefficients were estimated
to determine associations between adipokine concen-
trations and anthropometric measurements and bio-
chemical variables. Subjects were classified into tertiles
based on their circulating adipokines levels in the overall
population. Multivariable logistic regression analysis wasperformed to estimate odds ratios (ORs) adjusted for
covariates and to assess the predictive effect of adipo-
kines on risk for developing MetS. All data are re-
ported as Mean ± Standard Deviation (SD) and range,
unless stated otherwise. Research Electronic Data Capture
(REDCap) was used for data collections and data manage-
ment. All statistical assessments were two-sided and con-
sidered to be significant when P-value < 0.05. All analyses
were performed using SAS (version 9.2; SAS Institute,
Cary, NC).
Results
379 subjects (≥20 years of age) were interviewed and in-
cluded in this analysis, of which 50.9% were female.
Women and men had similar mean age (44.1 ± 11.9
years & 44.9 ± 11.5 years respectively). Generally, the
men had higher SBP and DBP, FBG, HbA1c, Triglyceride
and lower BMI, total cholesterol, HDL, and LDL than
women, as shown in Table 1. Overall, women presented
with higher circulating levels of hsCRP, leptin, PAI-1,
resistin, and adiponectin. There are insignificant differ-
ence in visfatin, and adipsin between women and men.
Age-sex adjusted Spearman partial correlations, Table 2,
showed that PAI-1 and adiponectin were significantly as-
sociated with most CVD risk factors. HsCRP showed
most association as it associated with all risk factors show-
ing strongest association with BMI and WC (R2 = 0.50,
p < 0.0001) and (R2 = 0.46, p < 0.0001) respectively. PAI-1
showed positive correlation with BMI, WC, SBP, DBP in
addition to HOMA-IR and TG and negative correlation
with HDL (p < 0.05). Resistin and adiponectin on the other
hand showed an opposite pattern of correlation. Resistin
showed negative correlation with SBP, DBP, FBG and
HOMA-IR (p < 0.05). Adiponectin showed negative
correlation with BMI, WC, SBP, FBG, HOMA-IR, TG
and positive correlation with HDL (p < 0.05). Increased
level of visfatin was associated with increased FBG,
HOMA-IR, TCHL, LDL, and TG and decreased HDL
level (p < 0.05). Similarly plasma leptin level was signifi-
cantly associated with BMI, WC as well as HOMA-IR
(p < 0.0001), Table 3.
After adjusting for age and gender subjects in the
highest tertile of leptin, PAI-1and hsCRP had higher
odds of having MetS (OR = 3.02, 95% CI = 1.47 – 6.19)
(P-trend = 0.0029), (OR = 2.52, 95% CI = 1.45 – 4.35)
(P-trend = 0.0037) (OR = 4.26, 95% CI = 2.39 – 7.59)
(P-trend < 0.0001) respectively. Subjects in the highest
tertile of adiponectin had lower odds of having MetS
(OR = 0.22, 95% CI = 0.12 – 0.40) (P-trend < 0.0001).
On the other hand, subjects in the highest tertiles of
resistin, adipsin and visfatin did not show any significant
association with MetS (Table 3). Age-gender adjusted
least square means of leptin, PAI-1, hsCRP and adipo-
nectin concentrations showed significant association
Table 1 Clinical and Socio-demographic characteristics of Arab population
Characteristics All (n = 379) mean ± SD Female (n = 193) mean ± SD Male (n = 186) mean ± SD P-value
Age (years) 44.4 ± 11.7 44.1 ± 11.9 44.9 ± 11.5 0.5109
BMI (kg/m2) 31.9 ± 6.4 33.2 ± 6.7 30.5 ± 5.8 <0.0001
WC (cm) 101.0 ± 14.3 99.3 ± 14.3 102.8 ± 14.1 0.0153
SBP (mmHg) 129.9 ± 19.8 124.8 ± 19.6 135.1 ± 18.5 <0.0001
DBP (mmHg) 78.3 ± 12.5 76.9 ± 12.6 79.8 ± 12.3 0.0252
FBG (mmol/L) 6.2 ± 3.02 5.9 ± 2.5 6.6 ± 3.5 0.0424
HbA1c (%) 6.1 ± 1.8 5.7 ± 1.4 6.5 ± 2.0 <0.0001
HOMA-IR 3.3 ± 3.9 3.4 ± 4.7 3.1 ± 3.0 0.4486
TC (mmol/L) 5.2 ± 1.1 5.3 ± 1.1 5.1 ± 1.2 0.0353
TG (mmol/L) 1.7 ± 1.2 1.5 ± 0.8 1.9 ± 1.4 0.0045
HDL cholesterol (mmol/L) 1.1 ± 0.4 1.3 ± 0.4 0.99 ± 0.2 <0.0001
LDL cholesterol (mmol/L) 3.3 ± 1.0 3.4 ± 1.0 3.3 ± 1.0 0.2305
Leptin (ng/mL) 4.76(0.20-41.6) 8.35(1.1-41.6) 2.57(0.20-25.6) <0.0001
PAI-1 (ng/mL) 6.87(1.06-29.3) 7.38(1.4-29.3) 5.94(1.06-19.0) <0.0001
Adiponectin (μg/mL) 12.9(1.86-152.1) 15.6(1.86-80.07) 10.6(2.20-152.1) <0.0001
Visfatin (ng/mL) 2.96(0.28-179.2) 3.01(0.30-14.9) 2.9(0.28-179.2) 0.6966
Adipsin (μg/mL) 1.46(0.01-7.5) 1.46(0.48-7.5) 1.46(0.01-5.02) 0.4050
Resistin (ng/mL) 2.82(0.43-13.4) 3.01(0.43-12.6) 2.46(0.56-13.4) 0.0002
hsCRP (μg/mL) 2.82(0.01-21.9) 4.53(0.01-21.9) 2.10(0.01-18.2) <0.0001
BMI, body mass index; BP, blood pressure; HDL, high-density lipoprotein; FBG, fasting blood glucose; LDL, low-density lipoprotein.
Results are reported as Mean ± SD except for non-normally distributed metabolic markers that are presented as Median (range).
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Increased leptin, PAI-1 and hsCRP plasma level was
directly associated with increased number of MetS
(P-trend < 0.05). Adiponectin showed opposite effects as
it was inversely associated to increased number of MetS
in this population (P-trend < 0.0001).
Discussion
The main objective of the current study was to identify
metabolic markers that are associated with traditional
cardiovascular disease risk factors and MetS in Arab
population. Our study showed sexual dimorphism in
plasma level of leptin, PAI-1, hsCRP, resistin and adipo-
nectin with women showing higher levels of these meta-
bolic markers in Arabs. hsCRP showed significant
positive correlation with all risk factors except for
HDL where it was inversely associated. Leptin, PAI-1
and adipsin showed positive correlation with BMI. Vis-
fatin level was not associated BMI level unlike other
adipokines. Adiponectin showed highest association
with CVD risk factors as it negatively associated with
age, BMI, sex, SBP, HOMA-IR and LDL. It was also
negatively associated with increased odds of MetS and
increasing MetS components. Lepetin and PAI on the
other hand were associated with higher odds of MetS
and with increasing number of MetS components. Takentogether, this data highlights some of the potential
role these metabolic markers play in development of
MetS and CVD as well as their diagnostic value in this
population.
HsCRP, PAI-1 and Leptin Association with Metabolic Risk
Factors and MetS
MetS is defined by different health organizations as a
cluster of metabolic risk factors that constitute an in-
creased risk for developing T2D and CVD [20] [21].
Central obesity, dislypidemia hypertension and hypergly-
cemia are key components in the definition of MetS
[21,22]. MetS is also characterized by a chronic low
grade inflammation condition [20,23]. Current definitions
of MetS lack a component that measures inflammation
status. HsCRP has been suggested as a sensitive marker
that is predictive of MetS as well as development of car-
diovascular problems [20,22-24]. Our data showed that
hsCRP correlated with all the measured risk factors and
was most predictive of the development of MetS in this
population. HsCRP strong association with increased
number of MetS components highlights its beneficial use
as prognostic marker for metabolic disorders in this popu-
lation as well.
Using a wide range of adipokines our current study
showed that women possessed higher circulating levels
Table 2 Spearman Correlation (p-value) of Metabolic Markers with cardio-metabolic risk factors
Markers BMI WC SBP DBP FBG HbA1c HOMA-IR TC HDL LDL TG
Leptin (ng/ml) 0.48 (<.0001) 0.45 (<.0001) 0.01 (0.9074) 0.08 (0.1239) −0.02 (0.6386) −0.1 (0.0614) 0.32 (<.0001) 0.02 (0.7071) −0.01 (0.8035) 0.02 (0.7113) 0.10 (0.0687)
Pai_1 (ng/ml) 0.20 (0.0002) 0.14 (0.0066) 0.11 (0.0318) 0.10 (0.0491) 0.06 (0.2188) −0.1 (0.0872) 0.20 (0.0002) 0.03 (0.5377) −0.18 (0.0009) 0.05 (0.3823) 0.21 (<.0001)
Adiponectin (μg/ml) −0.26 (<.0001) −0.21 (<.0001) −0.13 (0.0165) −0.17 (0.2107) −0.22 (<.0001) −0.18 (0.0007) −0.34 (<.0001) −0.08 (0.1212) 0.33 (<.0001) −0.10 (0.0509) −0.28 (<.0001)
Visfatin (ng/ml) 0.10 (0.0663) 0.02 (0.7477) 0.01 (0.8272) −0.01 (0.9019) 0.17 (0.0010) −0.01 (0.8821) 0.20 (0.0001) 0.13 (0.0138) −0.13 (0.0184) 0.13 (0.0179) 0.12 (0.0195)
Adpisin (ng/ml) 0.33 (<.0001) 0.3 (<.0001) 0.03 (0.6119) 0.10 (0.2710) −0.12 (0.0207) −0.15 (0.0048) 0.02 (0.6884) −0.08 (0.1235) −0.05 (0.2055) −0.10 (0.0523) 0.08 (0.1175)
Resistin (ng/ml) −0.07 (0.1751) −0.06 (0.2596) −0.11 (0.0448) −0.14 (0.0082) −0.14 (0.0074) −0.09 (0.0776) −0.14 (0.0006) −0.06 (0.28) −0.05 (0.3937) −0.04 (0.4869) −0.01 (0.8508)
hsCRP (μg/ml) 0.50 (<0.0001) 0.46 (<0.0001) 0.14 (0.0085) 0.16 (0.0029) 0.13 (0.0148) 0.19 (0.0004) 0.36 (<0.0001) 0.15 (0.0055) −0.18 (0.0008) 0.15 (0.0050) 0.15 (0.0046)

















Table 3 Multiple logistic regression models for MetS in relation to metabolic markers
Biomarkers T1 T2 T3 P-trend
Reference OR (95% CI) OR (95% CI)
Adiponectin (μg/ml) 1 0.38 (0.22 – 0.67) 0.22 (0.12 – 0.40) <0.0001
Leptin (ng/ml) 1 2.71 (1.46 – 5.02) 3.02 (1.47 – 6.19) 0.0029
PAI-1 (ng/ml) 1 1.81 (1.06 – 3.09) 2.52 (1.45 – 4.35) 0.0037
Visfatin (ng/ml) 1 1.01 (0.60-1.70) 1.13 (0.66-1.92) 0.8860
Adipsin (μg/ml) 1 1.17 (0.69-1.97) 1.48 (0.87-2.54) 0.3528
Resistin (ng/ml) 1 1.48 (0.86-2.55) 1.06 (0.62-1.81) 0.3015
hsCRP (μg/ml) 1 3.21 (1.85-5.58) 4.26 (2.39-7.59) <0.0001
The MetS models adjusted for age, and gender.
Tertile values are expressed as:
Adiponectin: T1 (<10.0; n = 127), T2 (10.0 – 16.41; n = 127), and T3 (>16.41; n = 125); Leptin: T1 (<3.27; n = 128), T2 (3.27 – 7.23; n = 126), and T3 (>7.23; n = 125);
Pai-1: T1 (<5.58; n = 129), T2 (5.58 – 8.00; n = 126), and T3 (>8.00; n = 124); Visfatin: T1 (2.43; n = 129), T2 (2.43 – 3.79; n = 126), and T3 (>3.79; n = 124); Adipsin:
T1 < (1.28; n = 127), T2 (1.28 – 1.65; n = 126), and T3 (>1.65; n = 126). Resistin: T1 (<2.35; n = 129), T2(2.35 – 3.40; n = 125), and T3 (>3.40; n = 125); hsCRP: T1 (<1.71;
n = 130), T2 (1.71 – 5.12; n = 125), T3 (>5.12; n = 124).
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markers showed a significant difference, it was highest for
leptin at almost three folds followed by adiponectin at 1.6
fold difference. This difference in leptin level for example
is consistent with levels reported in other studies such as
Zuo et al., reported that men had 1.45 ng/ml compared to
8.32 ng/ml in women [25]. This difference can be ex-
plained by the difference in sex hormones especially in
women as a result of menopause which reduces estrogen
production a factor that has been shown to lead to obesity
in women [26]. Consistent with data reported in literature
for other populations, leptin showed positive association
with BMI and HOMA-IR.
PAI-1 and adiponectin were remarkably associated
with seven and eight of the studied risk factors respect-
ively. PAI-1 is a serine protease inhibitor that plays an
important role in fibrinolysis due to its inhibition of
plasminogen activation [27]. Elevated blood levels of
PAI-1 have been linked to high reoccurrence events of
myocardial infarction ([28-30]), Atherosclerosis [31] and
MetS. The positive association of PAI-1 with all of the
risk factors, except for HDL, is in agreement with litera-
ture [12]. In accordance to our data, PAI-1 has been
shown to positively correlate with atherosclerosis risk
factors such as obesity, hyperinsulinemia and hypertri-
glyceridemia [32,33]. In general, PAI-1 positively associ-
ates with MetS and its components in our study. Other
studies have shown that PAI-1 level are reduced in re-
sponse to interventional therapies that leads to reduction
in MetS components such as insulin resistance or weight
reduction [34]. Thus, the predictive ability of PAI-1 for
CVD diminishes after adjusting for MetS components.
This suggests that MetS is a prerequisite to high PAI-1
blood circulating level [12]. It can also explain the lack
of association with as many markers in the multivariate
analysis in our population.Adiponectin, a cardio-protective adipokine
Adiponectin on the other hand associated with most
CVD risk factors at the univariate and multivariate level.
It associated with six of the risk factors showing the
strength of this marker in predicting CVD risk. We also
showed that decreasing concentration of adiponectin as-
sociated with an increasing number of CVD risk factors
particularly in women highlighting the gender difference.
The importance of adiponectin in CVD is well docu-
mented as its plasma level has been shown to be attenu-
ated by cardiac pathologies such as coronary artery
disease [35,36], hypertension [37] and myocardial infarc-
tion [38]. Further, low plasma levels of adiponectin are
associated with obesity, T2D and MetS which are main
CVD risk factors [39]. Adiponectin is believed to be a
cardio-protective cytokine due to its insulin sensitizing,
anti-inflammatory and antiatherogenic properties [11,40].
In Human, a reported single nucleotide polymorphism is
associated with a reduction in adiponectin plasma levels
leaving individuals with these mutations predisposed to in-
sulin resistance [41]. Iindividuals carrying this mutation
were highly susceptible to hypertension and coronary ar-
tery disease supporting the protective role this protein
plays [42].
Adipsin, visfatin and resistin association with metabolic
markers
Our data sheds light on the association between visfatin
and adipsin with CVD risk factors in Arab population.
No independent association between BMI and visfatin
was observed. Association between obesity and visfatin
has been contested with some studies showing positive
correlation with obesity [43] while others failed to show
any correlation [44]. One of the factors suggested for
this discrepancy was ethnicity [45]. The fact that we
show no association between visfatin and BMI emphasizes
Figure 1 Age-gender adjusted least square means of concentrations of adiponectin, leptin, and PAI-1 and hsCRP according to the
number of MetS components.
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association between the different biomarkers in different
ethnicities.
Adipsin on the other hand is a serine protease that has
been shown to be upregulated in obesity. It is involved
in triglyceride metabolism through the cleavage of com-
plement factor C3 to C3a that stimulates TG production
in adipose tissue [46]. Maresh et al. showed that adipsin
was upregulated in a type 1 diabetes model possibly to
compensate for the increased fat utilization in insulin-
deficient animals [46]. Our data shows a trend of in-
creased adipsin production in subjects with higher BMI
and WC that is consistent with the known function of
adipsin.
Resistin is another adipokines that was found to be in-
creased in a diet induced obesity mouse model, as well
as genetically modified diabetic and obese mouse models
[47]. Resistin was also found to be a mediator of insulin
resistance in rodents. Unlike rodents, resistin was pre-
dominantly expressed in monocytes and macrophages
[47]. Even though, resistin was associated with obesity
and insulin resistance in rodents, human data is conflict-
ing in this regard. Some studies show association with
obesity and insulin resistance while others do not show
any association or negative association [47-49]. Our data
shows negative association between resistin and HOMA-
IR, highlighting the importance of ethnic studies to better
understand the function of these metabolic markers.
Ethnicity and metabolic markers
Difference in the level of various metabolic markers be-
tween different ethnic groups is well documented and is
suggested as a main reason for the discrepancies re-
ported in different studies [14-17,50-52]. For example,
Caucasians have a higher level of adiponectin than other
ethnicities such as Asians or African Americans [13,53].
In a multiethnic study, Morimoto et al. reported signifi-
cant ethnic differences in the level of leptin, adiponectin,
IL-6 and CRP between Caucasians, Japanese Americans,
Latinos, African Americans and Native Hawaiians [17].
TNF-α on the other hand was the only biomarker that
did not show any significant difference [17]. This ethnic
difference in the plasma level of metabolic markers is
also reflected on the association between these markers
and various risk factors [16,45]. For example, Sulistyo-
ningrum et al. showed that decrease in adiponectin level
was associated with greater increase in insulin resistance
as measured by HOMA-IR in Aboriginals, Chinese, and
South Asians compared to Europeans [16].
Available data regarding the level of metabolic markers
in the Arab population are scarce. Therefore, this study
represents an important milestone in understanding the
role of these metabolic markers in Arabs. On the other
hand, studies linking various metabolic markers to thegenetic background and comparing Arabs to other ethnic-
ities are also scarce. However; Genetic variation in adipo-
nectin and its association with metabolic disorders is one
of the well studied markers in Arabs [54-57]. For example,
Mtiraoui et al. reported association between adiponectin
single nucleotide polymorphisms and T2D in Tunisian
Arabs [56]. In another study, Zadjali et al. showed that
rs266729 in the adiponectin gene was associated with
traits defining obesity in Arab population [54]. As a result,
such studies looking at the association between metabolic
markers genetic variants and metabolic disorders in Arabs
compared to other ethnicities will be crucial to better
understand the ethnic variation in this ethnicity.
Study strengths and limitations
The strength of the current study is the fact that it com-
prehensively investigates the correlation between the
CVD risk factors and adipokines in Arab population. It
also highlights the importance of hsCRP in predicting
MetS and potential use as a prognostic marker for in-
creased risk of T2D and CVD. Nonetheless, we have a
few limitations in this study that can be overcome in fu-
ture studies. The first one is the lack of comparison with
other populations especially Caucasians to establish the
level of adipokines in Arabs to a well studied population.
Establishing such a cohort will be a difficult task to do
in Kuwait where percentage of Caucasians is limited.
The second limitation regarding the study design, the
cross-sectional design used here makes it impossible to
determine any causal relationship between circulation
levels of adipokines and CVD. It would also be import-
ant to study the effect of nutrients in future studies as
they have been shown to modulate adipokines as re-
cently shown by Juanola-Falgarona et al. [58].
Conclusions
In conclusion, this study is one of the first studies to in-
vestigate the association of metabolic biomarkers level
with CVD risk factors and MetS in Arab population.
Our data demonstrated the positive association between
hsCRP, leptin and PAI-1 with increased number of CVD
risk factors, MetS and MetS components. We also
showed that adipsin was positively correlating with BMI
while visfatin showed no significant correlation with BMI;
both proteins did not correlate with MetS components in
this population. On the other hand, adiponectin was nega-
tively associated with many of the CVD risk factors and
MetS components showing its beneficial role in this popu-
lation as observed in other populations. In conclusion,
hsCRP, leptin, PAI-1 and adiponectin show strongest asso-
ciation with CVD risk factors and MetS in Arabs. Our
findings also emphasize the use of hsCRP as an important
measure of low grade inflammation and its association
with MetS.
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